CMS announces latest negotiated prices for 15 drugs to begin in 2027
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. The selected drugs are used to treat cancer, diabetes, asthma and other chronic conditions. CMS said the new pricing will take effect Jan. 1, 2027, and that Medicare Part D beneficiaries are expected to save $685 million in out-of-pocket costs as a result.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Feb. 25 released a request for information on potential regulatory changes in a possible future…
Headline
The Centers for Medicare & Medicaid Services Feb. 23 announced the development of its Medicare App Library. As part of the agency’s Health Technology…
Headline
The Congressional Budget Office has projected that the Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2040 — 12 years…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…
Headline
A JAMA study published Feb. 18 found that 10% of Medicare Advantage beneficiaries — approximately 2.9 million — have needed to find other health coverage for…